Noninvasive Testing
ECG changes may develop over time; therefore, individuals suspected of having ARVD/C who do not show these changes should undergo serial ECGs [Quarta et al 2010] .
E Ec ch ho oc ca arrd diio og grra ap ph hy y 3D echocardiography, an experimental imaging modality, may be useful in diagnosis, as right ventricular myocardial mechanics such as velocity, displacement, strain, and strain rate can be better assessed with 3D echocardiography than with conventional 2D echocardiography [Teske et al 2007] . However, interpretation is variable based on the center's expertise in reading 3D echocardiograms; guidelines have not been established. 3D echocardiography can be considered for persons with defibrillators for whom cardiac MRI is contraindicated .
C Ca arrd diia ac c M MR RII MRI images demonstrating ARVD are included in Murphy et al [2010] .
Cardiac MRI analysis should also include assessment of global and regional right ventricular function and right ventricular myocardial fibrosis.
Not all centers are experienced in the diagnosis of ARVD by cardiac MRI. Because identification of right ventricular free wall thinning and fatty infiltration on cardiac MRI in persons with a mild ARVD phenotype can be subject to a high degree of intra-observer variability, cardiac MRI is best performed in centers with experience. Cardiac MRI has not been able to detect early changes of ARVD in children; however, this could result from the absence of manifestations in children rather than a failure of the method [Fogel et al 2006] . Further studies are needed.
Invasive Testing
E Elle ec cttrro op ph hy yssiio ollo og giic c ((E EP P)) ssttu ud dy y ffiin nd diin ng gss.. Ventricular tachycardia easily induced with ventricular pacing and extrastimulation R Riig gh htt v ve en nttrriic cu ulla arr a an ng giio og grra ap ph hy y ((R RV VA A)) ffiin nd diin ng gss.. Enlarged right ventricle with segmental abnormalities R Riig gh htt v ve en nttrriic cu ulla arr e en nd do om my yo oc ca arrd diia all b biio op pssy y ffiin nd diin ng gss.. Fibrofatty replacement of the myocardium (predominantly in the apex, right ventricular outflow tract, and right ventricular inflow tract) and/or atrophy of the right ventricular myocardium Note: (1) The biopsy must sample an affected region to be diagnostic. 
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Note:
Guidelines for genetic testing recommendations are available [Hershberger et al 2009] . The Heart Rhythm Society/European Heart Rhythm Association published an Expert Consensus Statement for genetic testing for cardiomyopathies [Ackerman et al 2011] .
The overall yield of genetic testing for all available genes in probands who meet the revised Task Force criteria approximates 50% [Quarta et al 2011] . Thus, if molecular genetic testing does not identify a disease-causing mutation in an individual who meets diagnostic criteria, the clinical diagnosis of ARVD/C is unchanged.
Because of the complexity of interpreting genetic testing results (see also Clinical Description), Ackerman et al [2011] note that extreme caution should be taken in interpreting results. Consideration should be given to referring patients to specialty centers to perform the genetic testing.
Because of a significant level of reduced penetrance (see Penetrance), it may be appropriate to offer molecular genetic testing to simplex cases (i.e., a single occurrence of the clinical diagnosis of ARVD/C in a family).
Molecular genetic testing should be considered in individuals who are suspected of having ARVD/C based on criteria of the International Task Force , but who do not meet criteria for a definite clinical diagnosis. For some of these individuals, identification of a disease-causing mutation in one of the ARVD/C-related genes fulfills the remaining criteria.
Although some ARVD/C-related genes are more frequently mutated in ARVD/C than others (Table 1) Because ARVD/C multi-gene panels vary by methods used and genes included, the ability of a panel to detect a causative mutation(s) in any given individual also varies.
Genetic testing is also warranted in those who otherwise meet criteria of the Task Force [McKenna et al 1994, in order to identify the causative mutation and enable genetic testing of at-risk family members (see Management and Genetic Counseling). 2.
Summary of Molecular Genetic Testing Used in Arrhythmogenic Right
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G Ge en ne e ((L Lo oc cu uss N Na am me e)) P Prro op po orrttiio on n o off A AR RV VD D//C C A Attttrriib bu utte ed d tto o M Mu utta attiio on n o off T Th hiiss G Ge en ne e . CPVT, an autosomal dominant disorder characterized by stress-related, bi-directional ventricular tachycardia in the absence of both structural heart disease and a prolonged QT interval [Coumel et al 1978 , Leenhardt et al 1995 , may present with syncopal events in childhood and adolescence. Mutation of RYR2 has been associated with early cardiac death.
It has been suggested that CPVT and ARVD/C represent a phenotypic spectrum; however, families with both CPVT and ARVD have not been described, and unique RYR2 pathogenic variants have been associated with each disorder. Therefore, it is debated whether individuals with pathogenic variants in RYR2 should all be classified as having CPVT instead of some as having ARVD/C. P PK KP P2 2,, S SG G2 2,, T TG GF FB B3 3,, a an nd d T TM ME EM M4 43 3. . No other phenotypes have been associated with mutation of these genes.
Clinical Characteristics Clinical Description
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a myocardial disorder that predominantly affects the right ventricle. ARVD/C is a progressive disorder characterized by fibrofatty replacement of the myocardium, predisposing to ventricular tachycardia and sudden death in young individuals and athletes [Marcus et In a long-term study of 132 living affected individuals from 37 families, none were diagnosed in infancy and two were diagnosed at ages four and six years [Nava et al 2000] . The mean age at diagnosis was 31 years (±13; range: 4-64 years).
The principal characteristic of arrhythmogenic cardiomyopathies is the tendency for ventricular arrhythmia and sudden death in the absence of overt ventricular dysfunction. The increased risk for sudden death in ARVD/C is thought to relate to sudden ventricular arrhythmias.
A gender bias was identified with those with pathogenic variants in PKP2 (ARVD9). Among individuals with a heterozygous PKP2 mutation, 67% of males (compared to 35% of females) met Task Force criteria for diagnosis [McKenna et al 1994] ; however, gender differences in age of diagnosis or survival were not significant . Note that these findings may not be applicable to other genetic forms of ARVD/C.
Studies that have investigated the propensity to arrhythmia in ARVD include the following:
The risk of sudden death from ARVD/C is controversial [Firoozi et al 2003 , Tabib et al 2003 . In a study of 160 probands fulfilling clinical criteria for ARVD/C, 24 died during follow-up giving an overall mortality rate of 18.5% and an annual mortality rate of 2.3% [Hulot et al 2004] . Mean age at death (±SD) was 54 years (±19). Of the 24 deaths, 21 were cardiovascular deaths, among which seven were sudden cardiac deaths and 14 were a result of progressive heart failure (7 ventricular tachycardia or fibrillation occurring during an acute episode of severe cardiac failure, 5 terminal heart failure, and 2 rapid deaths after cardiac transplantation) [Hulot et al 2004] .
Lemola et al [2005] reported that of 24 persons with ARVD/C who received an implantable cardioverter-defibrillator (ICD), ten received appropriate shocks, four had inappropriate shocks, three had a heart transplant, one died of heart failure, and one died suddenly despite delivery of several device charges. The authors note that not every ICD discharge may be associated with an arrhythmia leading to sudden death; some arrhythmias occur in normal cardiac function and, therefore, the denotation of "appropriate shocks" may be misleading.
In a study of 100 persons with ARVD/C (diagnosed clinically or via autopsy), 31 experienced sudden cardiac death . Of those diagnosed with ARVD/C while living, the death-free survival rate was 94% in persons older than age 60 years (mainly as a result of receiving ICDs to prevent sudden cardiac death).
In a long-term study of 11 families with pathogenic variants in TMEM43, Hodgkinson et al [2005] found that 50% of males considered at high risk for sudden death associated with ARVD/C died by age 39 years and 50% of females considered at high risk died by age 71 years. Mortality in these families was reduced by 28% in males who received an ICD. In another study of 137 persons in 15 families, males had a median age of disease onset of 32 years and females 44 years [Merner et al 2008] . Penetrance was 100% by age 63 years in males and age 76 years in females. In this study, the relative risk of dying of sudden cardiac death was 6.8 times greater in affected males than affected females. , and DSG2) revealed lower than expected mutation rates, particularly in athletes performing the most exercise. These findings support the notion that intense exercise can induce ARVD/C without an identifiable genetic predisposition.
A multi-center study of 108 probands with ARVD/C revealed that 34% were competitive or professional athletes [Marcus et al 2009] . These studies lend further support to the hypothesis that vigorous or sustained athletic activity facilitates the phenotypic expression of the disease due to the repetitive stretch of the thin walled right ventricle with an underlying genetic desmosomal protein abnormality.
Pathogenic variants in desmosomal genes have also been identified in 5% of individuals meeting criteria for dilated cardiomyopathy. Although these individuals did not meet criteria for ARVD/C, some did have a history of ventricular arrhythmias and one individual had fibrofatty infiltration on autopsy, leading to the speculation that variants in these desmosomal genes can predispose to heart failure or ventricular arrhythmias [Elliott et C Co om mp po ou un nd d a an nd d d diig ge en niic c h he ette erro oz zy yg go ossiitty y o off d de essm mo osso om ma all g ge en ne ess iin n A AR RV VD D//C C.. Compound heterozygosity (mutation of both alleles of the same gene) and digenic heterozygosity (heterozygous mutation of two different genes) have been seen in autosomal dominant ARVD/C. Many studies have reported on two pathogenic variants in ARVD/C-related genes encoding demosomal proteins.
It is questioned whether certain heterozygous PKP2 mutations are sufficient to cause disease or if biallelic mutation is necessary [Xu et al 2010] . In an early study of six firstdegree relatives of a proband with a PKP2 pathogenic variant, two met clinical criteria for ARVD/C and four had either a normal phenotype or mild disease manifestations [Gerull et al 2004] . In a second family, two individuals with a PKP2 pathogenic variant died of sudden death at young ages, whereas of five living relatives with the pathogenic variant, only one met clinical criteria [Gerull et al 2004] . Subsequent reports have documented families in which relatives with the same pathogenic variant as the proband do not meet ARVD/C clinical criteria.
In 42% of individuals with ARVD, Xu et al [2010] identified either compound heterozygosity for two PKP2 mutations or digenic heterozygosity (one heterozygous PKP2 mutation and a second heterozygous mutation in an ARVD/C-related gene encoding a demosomal protein). Xu et al [2010] found a more severe phenotype in those who had compound and digenic heterozygosity when at least one mutation occurred in PKP2. In addition, they speculated that one pathogenic variant in PKP2 may not be sufficient to cause disease because some individuals with one PKP2 pathogenic variant did not meet revised Task Force criteria [McKenna et al 1994] , whereas those in the family with two pathogenic variants had ARVD.
Bauce et al [2010] found 7.1% of 42 index cases were compound heterozygotes or digenic heterozygotes. When those who were heterozygous for multiple mutations were compared to family members who were heterozygous for a single mutation, the phenotype ranged from no heart disease to severe disease with left ventricular and right ventricular dilatation being more severe in those who were heterozygous for multiple mutations than in those who were heterozygous for a single mutation.
Bauce et al [2010] also found that some individuals meeting ARVD diagnostic criteria had two pathogenic variants, but that other family members who had a single pathogenic variant did not have a clinical diagnosis of ARVD.
Barahona-Dussault et al [2010] reported that 43% of their ARVD population with mutations (38% of the study population met the McKenna et al [1994] Task Force criteria) had a pathogenic variant in an ARVD-related desmosomal gene, and of these, two (20%) were compound heterozygotes and one (10%) was a digenic heterozygote.
Nakajima et al [2012] found that four of seven probands who met Revised Task Force criteria for ARVD/C had two pathogenic variants: three were compound heterozygotes and one was a digenic heterozygote . , the study found no increase in frequency of compound or digenic heterozygous pathogenic variants in a cohort of young (age ≤21 years) individuals with ARVD/C compared to middle age and older affected individuals. Overall, more research is needed on the effects of pathogenic variants in ARVD/C-related desmosomal genes, and on whether some genes/mutations could have a more severe impact in the compound or digenic heterozygous state versus others that could manifest disease as a single heterozygous mutation.
Genotype-Phenotype Correlations
Currently, insufficient data limit genotype-phenotype correlations. Furthermore, marked variation in phenotype can be observed in individuals from the same family who have the same pathogenic Further studies are needed to establish the penetrance of ARVD/C caused by mutation of other genes.
Genetic variation in ARVD/C-related genes encoding proteins of desmosome structure/function (i.e., DSP, PKP2, DSG2, DSC2, and JUP) that would be considered rare and pathogenic have been identified in 16.2% of healthy Dutch controls compared to 58.3% of Dutch persons meeting 2010 revised Task Force criteria for ARVD/C -an approximately 3.5-fold higher rate in the latter [Kapplinger et al 2011] .
However, approximately one in six healthy controls genotyped had a variant in a gene encoding desmosomal proteins that would have been called pathogenic. Kapplinger et al observed that radical mutations (insertions/deletions, splice junction and nonsense mutations) were significantly more prevalent in persons with ARVD/C than in controls (49.9% vs. 0.47% respectively), leading them to propose that this type of genetic variant has a higher likelihood of being associated with ARVD/C pathogenicity. Regarding missense mutations, Kapplinger et al identified three associations with ARVD/C pathogenicity: rare missense mutations identified in a person of northern European origin is more likely pathogenic than one identified in a person of different origin; specific amino-terminal regions of DSP and DSG2 may contain mutation hot spots that have more missense mutations in persons with ARVD/C than controls; and missense mutations that involve a highly conserved residue in PKP2 and DSG2 are more likely pathogenic.
Kapplinger et al do address the concern that variants identified in a control population (with the majority being missense mutations) could be less penetrant in the heterozygous state compared to compound heterozygosity or digenic heterozygosity in those with ARVD/C.
Similarly, Lahtinen et al [2011] screened a Finnish ARVD/C population and general population samples and found pathogenic variants in ARVD/C-related genes encoding proteins of desmosome structure/function in one in 200 Finns, including identified founder mutations. Some of those with variants in the general population were actually symptomatic; however, the high mutation prevalence does demonstrate reduced penetrance for many in the general population, as the estimated prevalence of ARVD in the Finnish population is 1:1000 to 1:5000.
Andreasen et al [2013] found that for ARVD/C, 18% of the desmosomal variants previously classified in the literature as pathogenic were found in the Exome Sequencing Project population. This corresponds to a genotype prevalence of 1:5 when the prevalence in the general population is 1:5000, yielding an overrepresentation of genetic variants previously associated with cardiomyopathy in new population-based exome data and leading Andreasen et al to suspect that a high number of these variants may be disease modifiers, or possibly non-pathogenic.
Nomenclature
Arrhythmogenic right ventricular cardiomyopathy (ARVC) has had numerous names including Uhl anomaly and right ventricular dysplasia. Until 1996, ARVC was called arrhythmogenic right ventricular dysplasia (ARVD) [Richardson et al 1996] . Currently the terms ARVC and ARVD are used interchangeably.
Prevalence
The exact prevalence of ARVD/C is unknown but may be estimated at 1:1000 to 1:1250 in the general population [Peters 2006 ].
The prevalence of ARVD/C is greater in certain regions; in Italy and Greece (Island of Naxos), it can be as high as 0.4%-0.8% .
Differential Diagnosis
A AR RV VD D//C C a an nd d a an ntte erriio orr p po olla arr c ca atta arra ac ctt ((A AP PC C)).. A single family with ARVD/C and subscapular cataract, a rare hereditary form of lens opacity, has been described [Frances et al 1997] . The proband and his sister both had ARVD/C and APC. The gene responsible for APC previously was linked to 14q24qter. Parents of the sibs were second cousins. R Riig gh htt v ve en nttrriic cu ulla arr o ou uttffllo ow w ttrra ac ctt tta ac ch hy yc ca arrd diia a ((R RV VO OT T)) is a clinical arrhythmia condition that is not typically associated with structural heart disease as is seen in ARVD/C. ECG and cardiac imaging may be useful to distinguish these disorders.
B Brru ug ga ad da a ssy yn nd drro om me e is characterized by ST segment abnormalities in leads V -V on the ECG and a high risk of ventricular arrhythmias and sudden death. Considerable clinical overlap may be present. One discriminating factor: the right ventricular dilation and fibrofatty infiltration characteristic of ARVD/C is rarely seen in Brugada syndrome.
Management Evaluations Following Initial Diagnosis
To establish the extent of disease and needs of an individual diagnosed with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), the following evaluations are recommended if not performed at the time of diagnosis:
ECG
Echocardiogram and/or MRI, depending on the expertise of the imaging center Electrophysiology study to assess the risk of ventricular arrhythmias and assess the appropriateness of device insertion (such as an implantable cardioverter defibrillator). A cardiac catheter ablation of tissue causing abnormal rhythms can be performed during the electrophysiology study; however, ablation is typically not effective in individuals with ARVD/C because of the multiple sites of primary ventricular tachycardias.
Treatment of Manifestations
Most affected individuals live a normal lifestyle.
Management of individuals with ARVD/C is complicated by incomplete information on the natural history of the disease as well as variable expressivity of the disease. Management of patients should be individualized and based on the specific results of detailed investigation.
Management is focused on prevention of syncope, cardiac arrest, and sudden death (see Prevention of Primary Manifestations). Recent studies suggest that individuals who present with clinical signs of right heart failure and/or left ventricular dysfunction and have a history of ventricular tachycardia are at high risk and should be treated aggressively [Hulot et al 2004] .
Education regarding sudden death risk to affected adults and parents of affected children is an important aspect of management.
Heart transplantation is considered when ARVD/C has progressed to right or left ventricular heart failure. Severe diffuse biventricular involvement simulating dilated cardiomyopathy and requiring heart transplantation seems to be rare.
Prevention of Primary Manifestations
A An nttiia arrrrh hy ytth hm miia a m me ed diic ca attiio on nss Persons who appear to be at the highest risk for a fatal arrhythmia are those who have been resuscitated, are unresponsive to or intolerant of antiarrhythmic therapy, or have first-degree relatives with a history of sudden cardiac arrest.
The appropriate time to place an ICD in an individual at moderate risk for a fatal arrhythmia is not known because ICD efficacy in ARVD/C may be affected by progressive fibrofatty involvement of the right ventricle, which may obscure appropriate sensing of the ICD.
In one study, 44 of 67 persons with ARVD/C with ICDs received appropriate* shocks from their ICD for treatment of a sustained ventricular arrhythmia and 16 of 67 received inappropriate shocks for sinus tachycardia, supraventricular tachycardia/atrial fibrillation, or oversensing (i.e., adding an atrial rhythm to the ventricular beat or detecting more waves than are occurring, giving the appearance that the heart is beating faster than it actually is). However, it is difficult to determine whether the ventricular tachycardia was sustained or whether it would have self-corrected without the shock. This study found that appropriate ICD therapies occurred more frequently for persons with definite ARVD/C compared to those with probable ARVD/C. Nonetheless, nearly one third of those with probable ARVD/C received appropriate intervention from the ICD. Therefore, ICD placement should be considered even in those who do not meet 1994 international Task Force ARVD/C diagnostic criteria but have probable ARVD/C (i.e., meeting fewer criteria) and positive findings on electrophysiologic study .
*Note: 'Appropriate' refers to proper sensing and delivery of defibrillation based on device function.
Corrado et al [2010] studied 106 consecutive individuals with ARVD/C who received an ICD based on arrhythmic risk factors such as syncope, nonsustained ventricular tachycardia, familial sudden death, and inducibility at programmed ventricular stimulation. In follow up at 58 months, 24% had appropriate shock interventions; 16% had shocks for life-threatening ventricular flutter; and 43% with prior syncope experienced appropriate ICD intervention. They also found that syncope, nonsustained ventricular tachycardia, and left ventricular dysfunction were predictors of life-saving ICD intervention. The first appropriate intervention ranged from age 15 to 56 years. None of the 27 who had ICDs implanted because of a history of isolated familial sudden death (i.e., sudden death in an asymptomatic family member who had no prior cardiovascular events) experienced appropriate ICD discharges. Further studies with a larger number of asymptomatic individuals at risk for ARVD/C are needed to determine risks and to refine the recommendations for implantation of an ICD.
Surveillance
Screening for degree of cardiac involvement in persons diagnosed with ARVD/C is essential to ascertain severity and disease progression over time. Screening recommendations:
ECG, annually or more frequently depending on symptoms Echocardiogram, annually or more frequently depending on symptoms
Holter monitoring
Cardiac MRI, frequency depending on symptoms and findings
Agents/Circumstances to Avoid
Individuals with right ventricular dysplasia may be discouraged from vigorous athletic activity including competitive athletics because of the strain caused on the right heart; however, conflicting views exist on restriction of vigorous athletic activity in persons with ARVD/C or those at risk for ARVD/C (see Clinical Characteristics, Clinical Description for more details).
Evaluation of Relatives at Risk
It is appropriate to offer molecular genetic testing to relatives at risk for ARVD/C (even those under age 18 years) if the pathogenic variant(s) have been identified in an affected family member so that morbidity and mortality can be reduced by early diagnosis and treatment. Predictive testing should be offered in the context of formal genetic counseling.
Note: Consideration should be given to molecular testing of all ARVD/C-related genes versus site-specific testing because of the high rate of digenic heterozygosity (a heterozygous mutation in two different genes) If the family-specific pathogenic variant has been identified in the asymptomatic at-risk relative, screening for cardiac involvement is recommended yearly between ages ten and 50 years.
If genetic testing has not been performed or did not identify a pathogenic variant in an affected family member, screening for cardiac involvement is recommended for asymptomatic at-risk first-degree relatives every three to five years after age ten years.
Screening for cardiac involvement comprises the following [Hershberger et al 2009, Charron et al 2010]:
Medical history with attention to heart failure symptoms, arrhythmia, presyncope and syncope Of the 16 children under age ten years, none fulfilled 1994 ARVD/C diagnostic criteria.
Of the 18 children age 11-14 years, six (33%) were diagnosed with ARVD/C by the 1994 ARVD/C diagnostic criteria and all had ventricular arrhythmias (2 had mild disease, 2 moderate disease, and 2 severe disease).
Of the 19 children 14-18 years, eight (42%) were diagnosed with ARVD/C by the 1994 ARVD/C diagnostic criteria. Six (32%) had arrhythmic symptoms; all eight with the diagnosis of ARVD/C had ventricular arrhythmias (4 with sustained VT, 2 with nonsustained VT, 2 with PVCs); and on echocardiogram, one had mild disease, five had moderate disease, and two had severe disease. See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. -ED.
Mode of Inheritance
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is usually inherited in an autosomal dominant manner. It can also be inherited in a digenic or autosomal recessive manner.
If the proband has a specific syndrome associated with ARVD/C, such as Naxos disease or Carvajal syndrome, counseling for that autosomal recessive condition is indicated. Typically, one parent has one ARVD/C-causing allelic variant in the gene and the other parent has a different ARVD/C-causing allelic variant in the same gene. However, both parents should undergo confirmatory genetic testing because it is possible that one parent harbors both pathogenic variants on the same allele, which would subsequently alter inheritance and risk counseling.
Risk to Family Members -Autosomal Dominant
The parents may or may not have clinical findings.
In addition, a proband with autosomal dominant ARVD/C may have the disorder as the result of a new mutation. The proportion of cases caused by de novo mutation is unknown.
Recommendations for the evaluation of parents of a proband with apparent de novo mutation include cardiac MRI or echocardiogram, ECG, and molecular genetic testing if the mutation(s) have been identified in the proband.
Note: Although some individuals diagnosed with autosomal dominant ARVD/C have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset or reduced penetrance of the disease in the affected parent.
S Siib bss o off a a p prro ob ba an nd d
The risk to the sibs of the proband depends on the genetic status of the proband's parents.
If a parent of the proband is affected and/or has a pathogenic variant, the risk to the sibs of inheriting the pathogenic variant is 50%. If both parents have a pathogenic variant, the risk to sibs of inheriting two pathogenic variants is 25%, one variant is 50%, and neither variant is 25%.
When the parents are clinically unaffected, the risk to the sibs of a proband may be lower. Variable expressivity and reduced penetrance are common. 
The risk to other family members depends on the status of the proband's parents.
If a parent is affected or has a pathogenic variant, his or her family members are at risk.
Risk to Family Members -Digenic Inheritance
Digenic ARVD/C results from the presence of two pathogenic variants: one variant in one ARVD/C-related gene plus another variant in a different ARVD/C-related gene.
P Pa arre en nttss o off a a p prro ob ba an nd d
Typically, one parent has an ARVD/C-causing allelic variant in one gene and the other parent has an ARVD/C-causing allelic variant in a different gene. However, both parents should undergo confirmatory genetic testing because it is possible that one parent harbors both pathogenic variants and is asymptomatic.
S Siib bss o off a a p prro ob ba an nd d.. Assuming that each parent has one pathogenic variant, at conception each sib has a 75% chance of inheriting one or two ARVD/C-related variants (and being at increased risk of developing ARVD/C) and a 25% chance of not inheriting a pathogenic variant (and being unaffected).
O Offffssp prriin ng g o off a a p prro ob ba an nd d.. The risk to offspring of inheriting one or two pathogenic variants is 75%.
O Otth he err ffa am miilly y m me em mb be errss o off a a p prro ob ba an nd d.. Each sib of the proband's parents will have zero, one, or two ARVD/C-related allelic variants depending on the genetic status of the proband's parent.
Related Genetic Counseling Issues
See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.
C Co on nssiid de erra attiio on nss iin n ffa am miilliie ess w wiitth h a ap pp pa arre en ntt d de e n no ov vo o m mu utta attiio on n.. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that mutation occurred de novo in the proband. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.
F Fa am miilly y p plla an nn niin ng g
The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.
It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.
D DN NA A b ba an nk kiin ng g is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing
If the pathogenic variant(s) have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available either through a clinical laboratory or a laboratory offering custom prenatal testing.
Requests for prenatal testing for conditions which (like ARVD/C) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.
P Prre eiim mp plla an ntta attiio on n g ge en ne ettiic c d diia ag gn no ossiiss ((P PG GD D)) may be an option for families in which the pathogenic variant(s) have been identified.
Resources
GeneReviews 
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. -ED. Defects in intercellular connections are one pathogenic mode that leads to arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). This is suggested by mutation of the genes encoding two desmosomal proteins, desmoplakin (DSP) and plakoglobin (JUP), associated with ARVD8/Carvajal syndrome and ARVD12/Naxos disease, respectively.
Altered calcium homeostasis may provide another pathogenic pathway in ARVD/C as suggested by mutation of RYR2 (ARVD2). RYR2 has an important role in calcium release from the sarcoplasmic reticulum and the regulation of excitation-contraction coupling. An impaired intracellular calcium concentration and altered excitation-contraction coupling may predispose to arrhythmias. In addition, impaired intracellular calcium may lead to cellular necrosis, promoting fibrosis and adipose replacement .
A database of all variants in the genes listed below can be found in the 
RYR2
G Ge en ne e ssttrru uc cttu urre e.. The gene comprises 105 exons, coding a 565-kd monomer, making it one of the largest human genes. For a detailed summary of gene and protein information, see Table A , G Ge en ne e S Sy ym mb bo oll.
P Pa atth ho og ge en niic c a alllle elliic c v va arriia an nttss.. In a study by Tiso et al [2001] , four missense mutations were identified in four Italian families in highly conserved regions of RYR2. These mutations differ from those found in RYR2 in CPVT. Pathogenic variants in RYR2 have also been identified in 'atypical' long QT syndrome [Tester et al 2005] .
N No orrm ma all g ge en ne e p prro od du uc ctt.. The ryanodine receptor 2 regulates calcium flux in the intracellular space and mediates cardiac muscle excitation-contraction coupling .
A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. Mutation of RYR2 is thought to result in an uncontrolled calcium leak in the cardiac myocyte, leading to arrhythmia. A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. It is speculated that abnormalities in desmoplakin lead to desmosomal instability. Defective desmosomes cannot sustain the constant mechanical stress in contracting cardiomyocytes, resulting in cardiac dysfunction and cell death [Yang et al 2006] . N No orrm ma all g ge en ne e p prro od du uc ctt.. Similar to desmoplakin, plakophilin-2 is a protein of the desmosome and provides structural and functional integrity to adjacent cells.
A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. Abnormalities in plakophilin are thought to perturb intercellular connections and lead to arrhythmia.
DSG2
G Ge en ne e ssttrru uc cttu urre e.. The gene comprises 15 exons spanning 48.6 kb. For a detailed summary of gene and protein information, see Table A A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. The effect of an abnormal gene product is unknown at this point; loss of DSG2 results in early embryonic lethality in knockout mice.
DSC2
G Ge en ne e ssttrru uc cttu urre e.. The gene comprises 17 exons spanning 32 kb. For a detailed summary of gene and protein information, see Table A There is a variant that produces a frameshift (p.Ala897LysfsTer4; previously reported as p.Glu896fsTer900) that was originally reported as pathogenic; however, it has been identified in six (1.5%) of 400 control chromosomes and is therefore reclassified as a possibly rare variant that could affect phenotypic expression of other mutations that give rise to ARVD/C [De .
N No orrm ma all g ge en ne e p prro od du uc ctt.. Desmocollin-2 (DSC2) is ubiquitously expressed in desmosomal tissues and is the only one of three desmocollin isoforms present in cardiac tissue. DSC2 is found in two forms, a and b, produced by alternate splicing of exon 16. Desmocollins bind to desmogleins through their extracellular domains in a Ca2+-dependent manner and their cytoplasmic domains have binding sites for plakoglobin.
A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. Desmocollin mutations resulting in an isoform lacking the last 37 amino acid residues of the carboxyl-terminal domain of DSC2a are unable to bind plakoglobin. It is unknown how the mutations affect desmosome formation, but it is speculated that the result would be impaired desmosomes.
TGFB3
G Ge en ne e ssttrru uc cttu urre e.. The gene comprises seven exons. For a detailed summary of gene and protein information, see Table A , G Ge en ne e S Sy ym mb bo oll.
P Pa atth ho og ge en niic c a alllle elliic c v va arriia an nttss.. Two pathogenic variants have been described, one in the 5' untranslated region of the gene and the second in the 3' untranslated region of the gene .
N No orrm ma all g ge en ne e p prro od du uc ctt.. TGFB3 encodes for transforming growth factor beta-3, which encodes for a cytokine-stimulating fibrosis and modulates cell adhesion.
A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. It is currently unknown how mutation of TGFB3 causes ARVD/C.
TMEM43
G Ge en ne e ssttrru uc cttu urre e.. TMEM43 comprises 12 exons coding for 400 amino acids. For a detailed summary of gene and protein information, see Table A , G Ge en ne e S Sy ym mb bo oll.
P Pa atth ho og ge en niic c a alllle elliic c v va arriia an nttss.. In a study by Merner et al [2008] , one putative pathogenic variant, the missense change p.Ser358Leu, was identified in 15 families, all of Newfoundland ancestry. Whether this variant is the causative mutation requires further testing, as it may rather be a benign variant that is in linkage disequilibrium with the causal mutation. A second TMTM43 variant, p.Arg312Trp, seems to be a second founder mutation as it has been found in two Newfoundland probands and their families as well as a family from the United Kingdom; haplotype analysis showed that all share the disease-associated alleles and thus share an ancestral chromosome [Haywood et al 2013] .
N No orrm ma all g ge en ne e p prro od du uc ctt.. TMEM43 codes for a novel transmembrane protein. By bioinformatics analysis, the primary sequence suggests that this protein may be a target of PPARγ. Bioinformatics predicts the protein to be a membrane protein with several post-translational modification sites [Merner et al 2008] . Functional studies are needed.
A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. The pathogenic mechanism of the abnormal gene product is unknown. Selected JUP Variants A Ab bn no orrm ma all g ge en ne e p prro od du uc ctt.. Myocardial biopsy from an affected individual showed that N-cadherin and plakophilin-2 were expressed at control levels; however, plakoglobin, desmoplakin, and connexin 43 were significantly reduced at the intercalated discs.
In vivo models suggest that mutation of JUP affects the structure and distribution of mechanical and electrical cell junctions and could interfere with regulatory mechanisms mediated by Wnt-signaling pathways .
